v3.26.1
Segment Information (Details)
3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
segment
Jun. 30, 2025
USD ($)
Segment Information        
Number of operating segments | segment     1  
Number of reportable segments | segment     1  
Revenue   $ 2,733,000   $ 2,790,000
Research and development expenses:        
Total research and development expenses $ 1,101,000 2,291,000 $ 6,013,000 4,797,000
General and administrative expenses:        
Total general and administrative 3,479,000 1,691,000 5,513,000 4,445,000
Other operating income (1,405,000)   (1,405,000)  
Change in fair value of warrant liability (215,000) (146,000) (56,000) (26,659,000)
Other loss (income), net (d) 94,000 (188,000) 96,000 (368,000)
Net (loss) income (3,054,000) (915,000) (10,161,000) 20,575,000
Single reportable segment        
Segment Information        
Revenue   2,733,000   2,790,000
Research and development expenses:        
Preclinical & clinical development (85,000) 1,897,475 2,528,000 2,524,475
Personnel related 472,000 425,000 861,000 890,000
Other research and development 714,000 (31,475) 2,624,000 1,382,525
Total research and development expenses 1,101,000 2,291,000 6,013,000 4,797,000
General and administrative expenses:        
Professional & consulting fees 1,512,000 634,000 2,297,000 1,826,000
Personnel related 510,000 512,000 1,176,000 1,416,000
Other general and administrative 1,457,000 545,000 2,040,000 1,203,000
Total general and administrative 3,479,000 1,691,000 5,513,000 4,445,000
Other operating income (1,405,000)   (1,405,000)  
Change in fair value of warrant liability (215,000) (146,000) (56,000) (26,659,000)
Other loss (income), net (d) 94,000 (188,000) 96,000 (368,000)
Net (loss) income $ (3,054,000) $ (915,000) $ (10,161,000) $ 20,575,000